Hospital Outcomes of Breast Cancer Patients With Concurrent Atrial Fibrillation

Document Type

Conference Proceeding

Publication Date


Publication Title



Background: It was estimated that 4% of newly diagnosed breast cancer patients had new onset of atrial fibrillation (AF). Data on the impact of AF on the in-hospital outcomes of breast cancer patients are scarce.

Objective: This study aimed to determine and assess the in-hospital outcomes of breast cancer patients with concurrent AF.

Methods: Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older with a diagnosis of breast cancer between 2017 and 2020. We categorized the cohort into two groups depending on the occurrence of AF during hospitalization. The primary endpoint of our study was the in-hospital outcomes and complications of breast cancer patients with and without concurrent AF.

Results: 284,226 breast cancer patients were included in this study; 32,289 (11.4%, 76.5 ± 10.1 years of age) with concurrent AF and 251,937 (88.6%, 62.7 ± 14.0 years of age) without. Those with concurrent AF were associated with higher odds of early mortality (adjusted odds ratio [aOR]: 1.19; 95% confidence interval [CI]: 1.12- 1.27, p<0.01), prolonged index hospital stay (aOR: 1.11; CI: 1.06- 1.16, p<0.01), and non-home discharge (aOR: 1.42; CI: 1.35- 1.48, p<0.01). The length of hospital stay was longer in the group with concurrent AF than those without concurrent AF (mean 6.3 days vs. 5.7 days, p<0.01). During hospitalization, those with concurrent AF had higher odds of developing acute heart failure (aOR: 1.54; CI: 1.37- 1.74, p<0.01), cardiogenic shock (aOR: 1.42; CI: 1.04- 1.93, p=0.03), pulmonary edema (aOR: 1.26; CI: 1.06- 1.49, p=0.01), and cerebral infarction (aOR: 1.51; CI: 1.21- 1.89, p<0.01).

Conclusion: Breast cancer patients with concurrent AF had worse in-hospital outcomes and complications than those without concurrent AF.




Suppl 1

First Page



American Heart Association Scientific Sessions, November 11-13, 2023, Philadelphia, PA